

LISTING OF CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-185 (cancelled)

186. (currently amended) ~~The kit of claim 159 wherein the mixture comprises~~ **A kit for directionally ligating a double-stranded nucleic acid to a first adaptor sequence, the kit comprising:**

- (A) a first unmodified deoxynucleotidetriphosphate and modified deoxynucleotidetriphosphate pair, unmodified dNTP<sub>1</sub> and modified dNTP<sub>1</sub>, respectively, selected from the group consisting of (1) ~~the~~ **an** unmodified dATP and ~~the~~ **a** modified dATP, (2) ~~the~~ **an** unmodified dGTP and ~~the~~ **a** modified dGTP, (3) ~~the~~ **an** unmodified dCTP and **a** modified dCTP, (4) **an** unmodified dTTP and **a** modified dTTP, and (5) **an** unmodified dUTP and ~~the~~ **a** modified UTP;
- (B) a second unmodified deoxynucleotidetriphosphate and modified deoxynucleotidetriphosphate pair, unmodified dNTP<sub>2</sub> and modified dNTP<sub>2</sub>, respectively, selected from the group consisting of (1) ~~the~~ **an** unmodified dATP and the modified dATP, (2) ~~the~~ **an** unmodified dGTP and ~~the~~ **a** modified dGTP, (3) ~~the~~ **an** unmodified dCTP and ~~the~~ **a** modified dCTP, (4) ~~the~~ **an** unmodified dTTP and ~~the~~ **a** modified dTTP, and (5) ~~the~~ **an** unmodified dUTP and ~~the~~ **a** modified UTP, wherein said first and second pairs are different; and
- (C) **instructions for using the deoxynucleotidetriphosphate mixture in a procedure for directionally ligating a nucleic acid into a first adaptor sequence, wherein the adaptor sequence is a duplex nucleotide sequence for cohesive ligation to an end of an exonuclease digested amplification product;**

**wherein (1) said first and second pairs are different, (2) the ratio of the modified dNTP<sub>1</sub> to the modified dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is less than 51; (3) the unmodified dATP is selected from the group consisting of dATP and analogs thereof, the unmodified dGTP is selected from the group consisting of dGTP and analogs thereof, the unmodified dCTP is selected from the group consisting of dCTP and analogs thereof, the unmodified dTTP is selected from the group consisting of dTTP and analogs thereof, and the unmodified dUTP is selected from the group consisting of dUTP and analogs thereof, (4) the analogs of dATP, dGTP, dCTP, dTTP, and dUTP do not impart resistance against enzymatic degradation by an exonuclease relative to dATP, dGTP, dCTP, dTTP, and dUTP, respectively, when incorporated into a polynucleotide, and (5) the modified dATP, modified dGTP, modified dCTP, modified dTTP, or modified dUTP when incorporated into a polynucleotide imparts resistance, relative to dATP, dGTP, dCTP, dTTP, and dUTP, respectively, against enzymatic degradation by an exonuclease at the site of incorporation.**

187. (previously presented) The kit of claim 186 wherein the ratio of the modified dNTP<sub>1</sub> to the modified dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is less than 27.
188. (previously presented) The kit of claim 187 wherein the ratio of the modified dNTP<sub>1</sub> to the modified dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is less than 13.
189. (previously presented) The kit of claim 186 wherein the modified dNTP<sub>1</sub> and the modified dNTP<sub>2</sub> are alpha phosphate substituted deoxynucleotidetriphosphates.

190. (previously presented) The kit of claim 189 wherein the ratio of the modified dNTP<sub>1</sub> to the modified dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is between about 0.05 and 6.4.
191. (previously presented) The kit of claim 190 wherein the ratio of the modified dNTP<sub>1</sub> to the modified dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is between about 0.1 and 3.2.
192. (previously presented) The kit of claim 191 wherein the ratio of the modified dNTP<sub>1</sub> to the modified dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is between about 0.2 and 1.6.
193. (previously presented) The kit of claim 190 wherein the unmodified dNTP<sub>1</sub> is the unmodified dGTP, the unmodified dNTP<sub>2</sub> is the unmodified dATP, the modified dNTP<sub>1</sub> is an alpha thiophosphorano dGTP, and the modified dNTP<sub>2</sub> is an alpha thiophosphorano dATP.
194. (previously presented) The kit of claim 186 wherein the modified dNTP<sub>1</sub> and the modified dNTP<sub>2</sub> are alpha thiophosphorano deoxynucleotidetriphosphates.
195. (previously presented) The kit of claim 194 wherein the unmodified dNTP<sub>1</sub> is the unmodified dGTP, the unmodified dNTP<sub>2</sub> is the unmodified dATP, the modified dNTP<sub>1</sub> is an alpha thiophosphorano dGTP, and the modified dNTP<sub>2</sub> is an alpha thiophosphorano dATP.
196. (previously presented) The kit of claim 195 wherein the ratio of the alpha thiophosphorano dGTP to the alpha thiophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.8 and 5.3.

197. (previously presented) The kit of claim 195 wherein the ratio of the alpha thiophosphorano dGTP to the alpha thiophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.17 and 2.7.
198. (previously presented) The kit of claim 197 wherein the ratio of the alpha thiophosphorano dGTP to the alpha thiophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.33 and 1.33.
199. (previously presented) The kit of claim 198 wherein the ratio of the alpha thiophosphorano dGTP to the alpha thiophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is about 0.66.
200. (previously presented) The kit of claim 186 wherein the modified dNTP<sub>1</sub> and the modified dNTP<sub>2</sub> are alpha boranophosphorano deoxynucleotidetriphosphates.
201. (previously presented) The kit of claim 200 wherein the unmodified dNTP<sub>1</sub> is the unmodified dGTP, the unmodified dNTP<sub>2</sub> is the unmodified dATP, the modified dNTP<sub>1</sub> is an alpha boranophosphorano dGTP, and the modified dNTP<sub>2</sub> is an alpha boranophosphorano dATP.
202. (previously presented) The kit of claim 201 wherein the ratio of the alpha boranophosphorano dGTP to the alpha boranophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.05 and 6.4.
203. (previously presented) The kit of claim 202 wherein the ratio of the alpha boranophosphorano dGTP to the alpha boranophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.1 and 3.2.
204. (previously presented) The kit of claim 203 wherein the ratio of the alpha boranophosphorano dGTP to the alpha boranophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.2 and 1.6.

205. (previously presented) The kit of claim 204 wherein the ratio of the alpha boranophosphorano dGTP to the alpha boranophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is about 0.4.
206. (currently amended) **A kit for directionally ligating a double-stranded nucleic acid to a first adaptor sequence, the kit comprising: The kit of claim 159 further comprising**  
**(A) a deoxynucleotidetriphosphate mixture comprising:**  
**(1) (a) an unmodified dATP selected from the group consisting of dATP and analogs thereof, (b) an unmodified dGTP selected from the group consisting of dGTP and analogs thereof, (c) an unmodified dCTP selected from the group consisting of dCTP and analogs thereof, and (d) (i) an unmodified dTTP selected from the group consisting of dTTP and analogs thereof, or (ii) an unmodified dUTP selected from the group consisting of dUTP and analogs thereof; and**  
**(2) at least one modified deoxynucleotidetriphosphate selected from the group consisting of a modified dATP, a modified dGTP, a modified dCTP, a modified dTTP, and a modified dUTP;**  
**(B) a first adaptor sequence, wherein the first adaptor sequence comprises a nucleotide sequence encoding at least one epitope tag; and**  
**(C) instructions for using the deoxynucleotidetriphosphate mixture in a procedure for directionally ligating a nucleic acid into the first adaptor sequence;**  
**wherein (1) the analogs of dATP, dGTP, dCTP, dTTP, and dUTP do not impart resistance against enzymatic degradation by an exonuclease relative to dATP, dGTP, dCTP, dTTP, and dUTP, respectively, when incorporated into a polynucleotide; (2) the modified dATP, modified dGTP, modified dCTP, modified dTTP, or modified dUTP when incorporated into a polynucleotide imparts resistance, relative to dATP, dGTP, dCTP, dTTP, and dUTP, respectively, against enzymatic degradation by an exonuclease at the site**

**of incorporation; and (3) the adaptor sequence is a duplex nucleotide sequence for cohesive ligation to an end of an exonuclease digested amplification product.**

207. (previously presented) The kit of claim 206 wherein the first adaptor sequence comprises an epitope tag selected from the group consisting of c-myc, polyhistidine, polyarginine, glutathione-S-transferase (GST) tag, HA epitope, V5, and DYKDDDDK.
208. (previously presented) The kit of claim 207 wherein the first adaptor sequence comprises a DYKDDDDK epitope tag.
209. (previously presented) The kit of claim 206 further comprising a second adaptor sequence.
210. (previously presented) The kit of claim 209 wherein the second adaptor sequence comprises a nucleotide sequence encoding at least one epitope tag and the epitope tag comprises c-myc, polyhistidine, polyarginine, glutathione-S-transferase (GST) tag, HA epitope, V5, or sequence DYKDDDDK.
211. (previously presented) The kit of claim 210 wherein at least one epitope tag of the second adaptor sequence comprises the sequence DYKDDDDK.
- 212-214. (cancelled)
215. (currently amended) **A kit for directionally ligating a double-stranded nucleic acid to a first adaptor sequence, the kit comprising: The kit of claim 159 further comprising**  
**(A) a deoxynucleotidetriphosphate mixture comprising:**  
**(1) (a) an unmodified dATP selected from the group consisting of dATP and analogs thereof, (b) an unmodified dGTP selected from the group**

consisting of dGTP and analogs thereof, (c) an unmodified dCTP selected from the group consisting of dCTP and analogs thereof, and (d) (i) an unmodified dTTP selected from the group consisting of dTTP and analogs thereof, or (ii) an unmodified dUTP selected from the group consisting of dUTP and analogs thereof; and

(2) at least one modified deoxynucleotidetriphosphate selected from the group consisting of a modified dATP, a modified dGTP, a modified dCTP, a modified dTTP, and a modified dUTP;

(B) a first primer and a second primer; and

(C) instructions for using the deoxynucleotidetriphosphate mixture in a procedure for directionally ligating a nucleic acid into a first adaptor sequence;

wherein (1) the analogs of dATP, dGTP, dCTP, dTTP, and dUTP do not impart resistance against enzymatic degradation by an exonuclease relative to dATP, dGTP, dCTP, dTTP, and dUTP, respectively, when incorporated into a polynucleotide; (2) the modified dATP, modified dGTP, modified dCTP, modified dTTP, or modified dUTP when incorporated into a polynucleotide imparts resistance, relative to dATP, dGTP, dCTP, dTTP, and dUTP, respectively, against enzymatic degradation by an exonuclease at the site of incorporation; (3) a the first primer is complimentary to a first strand of the double-stranded nucleic acid, ~~the first primer having and has~~ a first terminus complimentary to a first ligation site sequence of the first adaptor sequence, and; (4) a the second primer is complimentary to a second strand of the double-stranded nucleic acid, ~~the second primer having and has~~ a second terminus complimentary to a second ligation site sequence of a second adaptor sequence; (5) ~~wherein~~ the first terminus of the first primer and the second terminus of the second primer are not identical; and (6) each adaptor sequence is a duplex nucleotide sequence for cohesive ligation to an end of an exonuclease digested amplification product.

216. (previously presented) The kit of claim 215 wherein the first terminus or the second terminus is about one to about ten nucleotides in length.
217. (previously presented) The kit of claim 216 wherein the first terminus or the second terminus is two to seven nucleotides in length.
218. (previously presented) The kit of claim 217 wherein the first terminus or the second terminus is two to five nucleotides in length.
219. (previously presented) The kit of claim 218 wherein the first terminus or the second terminus is four nucleotides in length.
220. (previously presented) The kit of claim 215 wherein the first terminus is a 3' terminus and the second terminus is a 3' terminus.
221. (previously presented) The kit of claim 215 wherein the first terminus is a 5' terminus and the second terminus is a 5' terminus.
222. (previously presented) The kit of claim 221 wherein the first terminus is four nucleotides in length, the second terminus is four nucleotides in length, and the first terminus and the second terminus are not identical.
- 223-227. (cancelled)
228. (previously presented) The kit of claim 215 further comprising instructions for using the deoxynucleotidetriphosphate mixture in a procedure for directionally ligating the nucleic acid into a second adaptor sequence.
229. (**currently amended**) A deoxynucleotidetriphosphate mixture comprising:  
(A) (1) an unmodified dATP selected from the group consisting of dATP and analogs thereof, (2) an unmodified dGTP selected from the group consisting of

dGTP and analogs thereof, (3) an unmodified dCTP selected from the group consisting of dCTP and analogs thereof, and (4) (a) an unmodified dTTP selected from the group consisting of dTTP and analogs thereof, or (b) an unmodified dUTP selected from the group consisting of dUTP and analogs thereof, ~~wherein the analogs of dATP, dGTP, dCTP, dTTP, and dUTP do not impart resistance against enzymatic degradation by an exonuclease relative to dATP, dGTP, dCTP, dTTP, and dUTP, respectively, when incorporated into a polynucleotide;~~ and

- (B) at least two modified deoxynucleotidetriphosphates selected from the group consisting of a modified dATP, a modified dGTP, a modified dCTP, a modified dTTP, and a modified dUTP; ~~wherein the modified dATP, modified dGTP, modified dCTP, modified dTTP, or modified dUTP when incorporated into a polynucleotide imparts resistance, relative to dATP, dGTP, dCTP, dTTP, and dUTP, respectively, against enzymatic degradation by an exonuclease at the site of incorporation.~~

wherein (1) the analogs of dATP, dGTP, dCTP, dTTP, and dUTP do not impart resistance against enzymatic degradation by an exonuclease relative to dATP, dGTP, dCTP, dTTP, and dUTP, respectively, when incorporated into a polynucleotide; and (2) the modified dATP, modified dGTP, modified dCTP, modified dTTP, or modified dUTP when incorporated into a polynucleotide imparts resistance, relative to dATP, dGTP, dCTP, dTTP, and dUTP, respectively, against enzymatic degradation by an exonuclease at the site of incorporation.

230. (currently amended) The dNTP mixture of claim 229 wherein the mixture comprises:

- (A) a first unmodified deoxynucleotidetriphosphate and modified deoxynucleotidetriphosphate pair, unmodified dNTP<sub>1</sub> and modified dNTP<sub>1</sub>, respectively, selected from the group consisting of (1) the unmodified dATP and the modified dATP, (2) the unmodified dGTP and the modified dGTP, (3) the

unmodified dCTP and the modified dCTP, (4) the unmodified dTTP and the modified dTTP, and (5) the unmodified dUTP and the modified UTP; and  
(B) a second unmodified deoxynucleotidetriphosphate and modified deoxynucleotidetriphosphate pair, unmodified dNTP<sub>2</sub> and modified dNTP<sub>2</sub>, respectively, selected from the group consisting of (1) the unmodified dATP and the modified dATP, (2) the unmodified dGTP and the modified dGTP, (3) the unmodified dCTP and the modified dCTP, (4) the unmodified dTTP and the modified dTTP, and (5) the unmodified dUTP and the modified UTP;<sub>2</sub>  
wherein said first and second pairs are different; and ~~wherein~~ the ratio of the modified dNTP<sub>1</sub> to the modified dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is less than 51.

231. (previously presented) The mixture of claim of 230 wherein the ratio of the modified dNTP<sub>1</sub> to the modified dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is less than 27.
232. (previously presented) The mixture of claim 231 wherein the ratio of the modified dNTP<sub>1</sub> to the modified dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is less than 13.
233. (previously presented) The mixture of claim 230 wherein the modified dNTP<sub>1</sub> and the modified dNTP<sub>2</sub> are alpha phosphate substituted deoxynucleotidetriphosphates.
234. (previously presented) The mixture of claim 233 wherein the ratio of the alpha phosphate substituted dNTP<sub>1</sub> to the alpha phosphate substituted dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is between 0.05 and 6.4.
235. (previously presented) The mixture of claim 234 wherein the ratio of the alpha phosphate substituted dNTP<sub>1</sub> to the alpha phosphate substituted dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is between 0.1 and 3.2.

236. (previously presented) The mixture of claim 235 wherein the ratio of the alpha phosphate substituted dNTP<sub>1</sub> to the alpha phosphate substituted dNTP<sub>2</sub> relative to the unmodified dNTP<sub>1</sub> to the unmodified dNTP<sub>2</sub> is between 0.2 and 1.6.
237. (previously presented) The mixture of claim 234 wherein the unmodified dNTP<sub>1</sub> is the unmodified dGTP, the unmodified dNTP<sub>2</sub> is the unmodified dATP, the modified dNTP<sub>1</sub> is an alpha thiophosphorano dGTP, and the modified dNTP<sub>2</sub> is an alpha thiophosphorano dATP.
238. (previously presented) The mixture of claim 233 wherein the modified dNTP<sub>1</sub> and the modified dNTP<sub>2</sub> are alpha thiophosphorano deoxynucleotidetriphosphates.
239. (previously presented) The mixture of claim 238 wherein the unmodified dNTP<sub>1</sub> is the unmodified dGTP, the unmodified dNTP<sub>2</sub> is the unmodified dATP, the modified dNTP<sub>1</sub> is an alpha thiophosphorano dGTP, and the modified dNTP<sub>2</sub> is an alpha thiophosphorano dATP.
240. (previously presented) The mixture of claim 239 wherein the ratio of the alpha thiophosphorano dGTP to the alpha thiophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.8 and 5.3.
241. (previously presented) The mixture of claim 239 wherein the ratio of alpha thiophosphorano dGTP to the alpha thiophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.17 and 2.7.
242. (previously presented) The mixture of claim 241 wherein the ratio of the alpha thiophosphorano dGTP to the alpha thiophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.33 and 1.33.

243. (previously presented) The mixture of claim 242 wherein the ratio of the alpha thiophosphorano dGTP to the alpha thiophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is about 0.66.
244. (previously presented) The mixture of claim 233 wherein the modified dNTP<sub>1</sub> and the modified dNTP<sub>2</sub> are alpha boranophosphorano deoxynucleotidetriphosphates.
245. (previously presented) The mixture of claim 244 wherein the unmodified dNTP<sub>1</sub> is the unmodified dGTP, the unmodified dNTP<sub>2</sub> is the unmodified dATP, the modified dNTP<sub>1</sub> is an alpha boranophosphorano dGTP, and the modified dNTP<sub>2</sub> is an alpha boranophosphorano dATP.
246. (previously presented) The mixture of claim 245 wherein the ratio of the alpha boranophosphorano dGTP to the alpha boranophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.05 and 6.4.
247. (previously presented) The mixture of claim 246 wherein the ratio of the alpha boranophosphorano dGTP to the alpha boranophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.1 and 3.2.
248. (previously presented) The mixture of claim 247 wherein the ratio of the alpha boranophosphorano dGTP to the alpha boranophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is between 0.2 to 1.6.
249. (previously presented) The mixture of claim 248 wherein the ratio of the alpha boranophosphorano dGTP to the alpha boranophosphorano dATP relative to the unmodified dGTP to the unmodified dATP is about 0.4.
250. (**currently amended**) A kit for directionally ligating a double-stranded nucleic acid to a first adaptor sequence, the kit comprising:

- (A) a deoxynucleotidetriphosphate (dNTP) mixture, the dNTP mixture comprising modified dNTPs for at least one of the four nucleotide triphosphates comprising dATP, dGTP, dCTP, dTTP and analogs thereof, which, when incorporated into a polynucleotide, impart resistance against enzymatic degradation by an exonuclease at the site of incorporation of the modified dNTPs; and
- (B) a first adaptor sequence, ~~wherein the first adaptor sequence comprises~~ **comprising** a nucleotide sequence encoding at least one epitope tag; and
- (C) instructions for using the deoxynucleotidetriphosphate mixture in a procedure for directionally ligating a nucleic acid into a first adaptor sequence.

251. (previously presented) The kit of claim 250 wherein the first adaptor sequence comprises an epitope tag selected from the group consisting of c-myc, polyhistidine, polyarginine, glutathione-S-transferase (GST) tag, HA epitope, V5, and DYKDDDDK.

252. (previously presented) The kit of claim 251 wherein the first adaptor sequence comprises a DYKDDDDK epitope tag.

253. (previously presented) A kit for directionally ligating a double-stranded nucleic acid to a first adaptor sequence, the kit comprising:

- (A) a deoxynucleotidetriphosphate mixture comprising:
  - (1) (a) dATP, (b) dGTP, (c) dCTP, and (d) dTTP; and
  - (2) at least one modified deoxynucleotidetriphosphate selected from the group consisting of a modified dATP, a modified dGTP, a modified dCTP, a modified dTTP, and a modified dUTP wherein the modified dATP, modified dGTP, modified dCTP, or modified dTTP when incorporated into a polynucleotide imparts resistance, relative to dATP, dGTP, dCTP, and dTTP, respectively, against enzymatic degradation by an exonuclease at the site of incorporation;

- (B) a first primer complimentary to a first strand of the double-stranded nucleic acid, the first primer having a first terminus complimentary to a first ligation site sequence of the first adaptor sequence;
- (C) a second primer complimentary to a second strand of the double-stranded nucleic acid, the second primer having a second terminus complimentary to a second ligation site sequence of a second adaptor sequence, wherein the first terminus of the first primer and the second terminus of the second primer are not identical;
- (D) an exonuclease;
- (E) at least one polymerase; and
- (F) instructions for using the deoxynucleotidetriphosphate mixture in a procedure for directionally ligating a nucleic acid into a first adaptor sequence and a second adaptor sequence, wherein the adaptor sequences are duplex nucleotide sequences for cohesive ligation to an end of an exonuclease digested amplification product.

254. (previously presented) The kit of claim 253 further comprising:

- (G) the first adaptor sequence, wherein the first adaptor sequence comprises a DYKDDDDK epitope tag; and
- (H) the second adaptor sequence.

255. (previously presented) The kit of claim 254 wherein the modified deoxynucleotidetriphosphates consist of an alpha thiophosphorano dGTP and an alpha thiophosphorano dATP.

256. (previously presented) The kit of claim 255 wherein the first primer has a 5' terminus and the second primer has a 5' terminus.

257. (previously presented) The kit of claim 256 wherein the exonuclease is an exonuclease III.

258. (previously presented) The kit of claim 257 wherein at least one polymerase is a Taq polymerase or a recombinant Taq polymerase.

259. (previously presented) The kit of claim 258 wherein there are at least two polymerases.